Study of adverse drug reaction of intravesical onco-BCG in non-muscle-invasive bladder cancer: a retrospective study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20252584Keywords:
Adverse drug reactions, European Association of Urology, Non-muscle invasive bladder cancer, OncoBCG Moscow strainAbstract
Background: Intravesical onco-BCG is mainstay therapy for intermediate and high‑risk NMIBC to reduce disease recurrence and progression. In India Danish 1331 strain was used till middle of last decade after that Moscow (Russia) strain is used.
Methods: Retrospective study was conducted in intermediate and high risk NMIBC patients. Patients receiving were interviewed for ADR’s and were recorded as grade 1, grade 2, grade 3 symptoms (as per Cleveland clinic approach to management of BCG toxicity). The patients with NMIBC (Ta or T1 diseases as per TNM staging AJCC 8th edition) in intermediate and high-risk group were enrolled in the study. The diseases classified in low risk, intermediate risk and high risk as per EAU guidelines.
Results: Sixty patients were enrolled in the study. Mean age of the patients is 62.75 years with male: female ratio 20:1. 46.6% of patients had intermediate and 53.4% had high risk disease. Mean follow-up period in the study was 32.27 weeks. 93.4% of patients had grade 1 symptoms and 6.6% had grade 2 symptoms. None of the patients had grade 3 serious complications.
Conclusions: Intravesical OncoBCG (Moscow strain) is safe and well tolerated in study population.
Metrics
References
Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette‑Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180‑3. DOI: https://doi.org/10.1016/S0022-5347(17)58737-6
Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette‑Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124:38‑40. DOI: https://doi.org/10.1016/S0022-5347(17)55282-9
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology guidelines on non‑muscle‑invasive bladder cancer (TaT1 and carcinoma in situ)- 2019 update. Eur Urol. 2019;76:639‑57. DOI: https://doi.org/10.1016/j.eururo.2019.08.016
Thyavihally YB, Dev P, Waigankar S, Pednekar A, Athikari N, Raut A, et al. Intravesical bacillus Calmette‑Guerin (BCG) in treating non‑muscle invasive bladder cancer- analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow). Asian J Urol. 2021;8:315‑23. DOI: https://doi.org/10.1016/j.ajur.2021.05.002
Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine. 1999;17:915‑22. DOI: https://doi.org/10.1016/S0264-410X(98)00277-1
Gan C, Mostafid H, Khan MS, Lewis DJ. BCG immunotherapy for bladder cancer- the effects of substrain differences. Nat Rev Urol. 2013;10:580‑8. DOI: https://doi.org/10.1038/nrurol.2013.194
Kamat MR, Kulkarni JN, Tongaonkar HB, Dalal AV. Intravesical bacillus Calmette‑Guerin for superficial bladder cancer: Experience with Danish 1331 strain. J Urol. 1994;152:1424‑8. DOI: https://doi.org/10.1016/S0022-5347(17)32436-9
Quan Y, Jeong CW, Kwak C, Kim HH, Kim HS, Ku JH. Dose, duration and strain of bacillus Calmette‑Guerin in the treatment of nonmuscle invasive bladder cancer: Meta‑analysis of randomized clinical trials. Medicine. 2017;96:e8300. DOI: https://doi.org/10.1097/MD.0000000000008300
Vijjan V, Mandhani A, Kapoor R, Dubey D, Srivastava A, Ansari M, et al. A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette‑Guerin for superficial bladder cancer. Indian J Urol. 2006;22:317. DOI: https://doi.org/10.4103/0970-1591.29117
Agrawal MS, Agrawal M, Bansal S, Agarwal M, Lavania P, Goyal J. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma. Urology. 2007;70:1075‑8. DOI: https://doi.org/10.1016/j.urology.2007.07.017
Downloads
Published
How to Cite
Issue
Section
